Introduction {#Sec1}
============

Esophageal cancer is the eighth most frequent type of cancer in the world and the sixth most lethal, occurring mainly in developing countries such as Brazil \[[@CR1]\]. The most frequent histological subtype is esophageal squamous cell carcinoma (ESCC), accounting for 90% of cases, especially in high-risk areas \[[@CR2]\]. The main risk factors for ESCC are alcohol consumption, tobacco (mainly in association) and hot-beverage consumption \[[@CR3]\]. It is also reported that chronic diseases, such as the chagasic megaesophagus, can be associated with ESCC development \[[@CR4]\].

Chagasic megaesophagus is the late manifestation of Chagas' disease (caused by the protozoan *Trypanosoma cruzi*) \[[@CR5]\]. Direct infection of *Trypanosoma cruzi* will lead to destruction of the intramural myenteric neurons in the esophagus, causing inflammation and production of neurotoxins. This will result in uncoordinated contractions and reduction of peristalsis of the organ, altering the functioning of the lower esophageal sphincter and progressive dilation of the esophagus (megaesophagus) \[[@CR6]\]. In Brazil, one of the endemic regions of Chagas' disease, approximately 4 million people are infected with the parasite and about 6--7% of these patients will develop chagasic megaesophagus \[[@CR5]\]. Patients affected with this lesion are more likely to develop ESCC (3--10%) when compared to the general population \[[@CR4]\].

The carcinogenic mechanisms of ESCC development in the context of chagasic megaesophagus have been little explored. Recently, our group showed the high frequency (13/32, 40.6%) of *TP53* mutations in ESCC associated with chagasic megaesophagus \[[@CR7]\]. Moreover, we also reported the presence of microsatellite instability (MSI) in a small fraction (1/19, 5.3%) of cases \[[@CR8]\]. However, many other genes are known to be involved in ESCC carcinogenesis as demonstrated by the TCGA consortium \[[@CR9]\].

One of these genes is the *PI3KCA*, which encodes the protein phosphatidylinositol 3-kinase (PI3K), that belongs to a family of lipid kinases that encodes the p110α catalytic subunit \[[@CR10]\]. PI3K is a quite complex signaling pathway since it regulates cell growth, proliferation, cell motility, the production of new proteins, apoptosis and cell survival \[[@CR10]\]. Therefore, its activation will lead to many downstream pathways that regulate several cellular functions, including those involved in the development of cancer \[[@CR10], [@CR11]\]. Recurrent *PI3KCA* oncogenic mutations were identified in several types of tumors, including colorectal, breast, ovary, gastric, and recently in ESSC \[[@CR12]\]. The mutations occur mainly in exons 9 (E542K and E545K) and 20 (H1047R) \[[@CR12]\]. Recently, it was shown that *PIK3CA* mutations, namely H1047R, also disrupt cellular genetic stability, increasing the frequency of chromosomal errors and leading to tetraploidy \[[@CR13]\]. Importantly, therapeutic strategies targeting the PIK3/Akt signaling pathway have been developed and could constitute effective treatment options for patients harboring *PI3KCA* mutations \[[@CR14]\].

Therefore, in the current study we performed the mutation analysis of *PIK3CA* gene in patients with ESCC and chagasic megaesophagus associated or not with ESCC, and searched for associations between the mutation status and patients' clinical and pathological features.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

In this retrospective study, we analyzed 89 formalin-fixed paraffin-embedded (FFPE) tissues of three groups of patients: i) 23 patients with chagasic megaesophagus associated with esophageal squamous cell carcinoma (CM/ESCC); ii) 38 patients with esophageal squamous cell carcinoma without chagasic megaesophagus (ESCC); and iii) 28 patients with chagasic megaesophagus without esophageal squamous cell carcinoma (CM). All chagasic megaesophagus patients were serologic positive for Chagas' disease and/or had exams (imaging and histopathology) that confirmed the presence of megaesophagus. The patients with esophageal squamous cell carcinoma without chagasic megaesophagus were all serologic negative for Chagas' disease and had exams (imaging and histopathology) that confirmed malignant disease. These patients were previously described for their clinical-pathological and molecular *TP53* and MSI features \[[@CR7], [@CR8]\].

The samples were obtained from patients treated between 1990 and 2016 in three different institutions from the Southeast of Brazil, namely: Barretos Cancer Hospital, Barretos, São Paulo State; Federal University of Triângulo Mineiro (UFTM), Uberaba, Minas Gerais State and São Paulo State University (UNESP), Botucatu, São Paulo State. All clinical and pathological information was obtained through medical record review.

DNA isolation {#Sec4}
-------------

Following tissue macro-dissection, DNA was isolated from FFPE tissue representative of the tumor lesions in ESCC and CM/ESCC groups and esophageal tissues in CM group, as previously described \[[@CR7]\]. Briefly, the tumor area was delineated in a hematoxylin-eosin stained (HE, Merck KGaA, GE) section by a pathologist, and the marked area was scraped by scalp from 3 to 5 10 μm unstained slides into a 1,5 ml tube. Afterwards, the tissue was subjected to the dewaxing step by heating (80 °C -- 20 min), followed by sequential washing in xylol (5 min) and decreasing concentrations of ethanol (1 min - 100, 70 and 50%) and nuclease-free water9 (1 min). DNA isolation was performed using the QIAamp DNA Micro Kit (Qiagen) following the manufacture's protocol.

*PIK3CA* mutation analysis {#Sec5}
--------------------------

Polymerase chain reaction (PCR) followed by direct sequencing (Sanger method) was performed for the analysis of hotspot mutations (exons 9 and 20) of the *PIK3CA* gene as previously described \[[@CR15]\]. The PCR was performed on the 89 samples under the following conditions: 5X Flexi Buffer (pH 8.5) and 25 mM MgCl2 (Promega, USA), 200 μM dNTPmix (Invitrogen, USA), 200 nM primers exon 9 (forward 5'-CTGTGAATCCAGAGGGGAAA-3′ and reverse 5'-ACATGCTGAGATCAGCCAAAT-3′) and exon 20 (forward 5'-ATGATGCTTGGCTCTGGAAT-3′ and reverse 5'-GGTCTTTGCCTGCTGAGAGT-3′), 1.25 U GoTaq®Hot Start Polymerase (Promega, USA), and nuclease-free water (Gibco, BRL, Life Technologies, USA) in a final volume of 25 μl and 5 μl of DNA at 50 ng/μl from each patient were added \[[@CR15]\]. Amplification was performed in a thermocycler according to the protocol: 96 °C for 15 min, followed by 40 cycles at 96 °C for 45 s, 55.5 °C for 45 s and 72 °C for 45 s and final extension of 72 °C for 10 min, followed by a hold at 4 °C. PCR products were subjected to 1.5% agarose gel electrophoresis with Gel Red (Biotium, Hayward, CA) to evaluate the amplification of the gene of interest.

After agarose gel validation, we purified the preparation using the enzyme ExoSap-IT (GE Technology, Cleveland, USA), followed by the sequencing reaction using BigDye Terminator v3.1 (Applied Biosystems, USA) and 3.2 μM of specific primers and re-purified with xTerminator (Life Technology). The products were sequenced using the 3500 series Genetic Analyzer Capillary Sequencer (Applied Biosystems, USA). All the cases that showed mutations were confirmed with a new PCR reaction and direct sequencing.

Statistical analysis {#Sec6}
--------------------

Characterization of the study population was performed through frequency tables for qualitative variables, and measures of central tendency and dispersion (mean, standard deviation, minimum and maximum) for the quantitative variables, comparing the different groups. To verify the association between *PIK3CA* mutation status and clinical groups, pathological and molecular features, Chi-square or Fisher's exact tests were applied. We performed an overallsurvival analysis using the Kaplan-Meier limit estimator and the Log-rank test to compare the survival curves between the groups.

The level of significance adopted was 5% (*p* ≤ 0.05). Statistical analyzes were in SPSS software v.21.0.

Results {#Sec7}
=======

Characterization of the population {#Sec8}
----------------------------------

The clinical-pathological characteristics of the patients in the three groups are described in Table [1](#Tab1){ref-type="table"}. The mean age of the patients was higher in the chagasic groups (Table [1](#Tab1){ref-type="table"}). As already reported in our previous studies \[[@CR7]\], concerning risk factors for esophageal cancer, the ESCC and CM/ESCC groups were statistically associated with higher tobacco and alcohol consumption (Table [1](#Tab1){ref-type="table"}).Table 1The clinical-pathological features of the three groups of patientsVariableGroups (*n* = 89)CategoryCM/ESCC (*n* = 23)ESCC (*n* = 38)CM (*n* = 28)*p*-valueGenderFemale4 (17.4%)7 (18.4%)4 (14.3%)0.937^\*\*^Male19 (82.6%)31 (81.6%)24 (85.7%)Age (years)Mean (SD)59 (11)57 (9)59 (11)**0.039** ^**\*\*\***^Min - Max37--7636--7537--76Alcohol consumptionNo7 (31.8%)8 (21.1%)20 (71.4%)**\< 0.001** ^**\***^Yes15 (68.2%)30 (78.9%)8 (28.6%)Missing1100Tobacco consumptionNo4 (18.2%)6 (15.8%)16 (57.1%)**\< 0.001** ^**\***^Yes18 (81.8%)32 (84.2%)12 (42.9%)Missing100Tumor differentiationWell differentiated5 (22.7%)7 (19.4%)NA0.639^\*\*^Moderate differentiated16 (72.7%)24 (66.7%)NAPoorly differentiated1 (4.5%)5 (13.9%)NAMissing12NATNM StagingI/II4 (23.5%)16 (42.1%)NA0.235^\*^III/IV13 (76.5%)22 (57.9%)NAMissing60NAMegaesophagus gradesGI/GII10 (45.5%)NA4 (14.3%)**0.025** ^**\***^GIII/GIV12 (54.5%)NA24 (85.7%)Missing1NA0^\*^Chi-square association test; ^\*\*^Fisher's exact test; ^\*\*\*^Analysis of variance. CM/ESCC -- chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC -- esophageal squamous cell carcinoma without chagasic megaesophagus; CM -- chagasic megaesophagus without esophageal squamous cell carcinoma; SD - standard deviation; NA -- not applicable; Bold numbers - statistical significance 

Mutation analysis of *PIK3CA* gene {#Sec9}
----------------------------------

The *PIK3CA* mutation analysis showed the presence of mutations in 21.7% of patients in CM/ESCC group, followed by 10.5% in ESCC group and 3.6% in CM group (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). The frequency of mutations was similar in exons 9 and 20 (Table [3](#Tab3){ref-type="table"}). With the exception of three variants (A1027D, K1030R and T1053K), all the other mutations have already been reported in the Catalogue of Somatic Mutations in Cancer database -- COSMIC (<http://cancer.sanger.ac.uk/cosmic>) (Fig. [2](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}).Fig. 1Electropherogram of *PIK3CA* gene. Exon 9 -- wild-type sequence and mutated sequence (D549H). Exon 20 -- wild-type sequence and mutated sequence (H1047R)Table 2Frequency of *PIK3CA* mutations in the three study groupsVariableGroups (*n* = 89)CategoryCM/ESCC (*n* = 23)ESCC (*n* = 38)CM (*n* = 28)*p*-value*PIK3CA* geneWT18 (78.3%)34 (89.5%)27 (96.4%)0.132^\*\*^MUT5 (21.7%)4 (10.5%)1 (3.6%)^\*\*^Fisher's exact test. CM/ESCC -- chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC -- esophageal squamous cell carcinoma without chagasic megaesophagus; CM -- chagasic megaesophagus without esophageal squamous cell carcinoma. WT -- wild-type; MUT -- mutant; N -- number of casesTable 3Profile of oncogenic *PIK3CA* mutations in the three study groupsGroupSample IDExonCodonCodon (WT -- MUT)Type of mutationAmino acids changeNature of mutationCOSMIC IDCM/ESCC111 T9545GAG -- GCAA → CE545AMissenseCOSM12458122 T9549GAT -- CATG → CD549HMissenseCOSM219119114 T201027GCC -- GACC → AA1027DMissenseNot reported119 T201047CAT -- CTTA → TH1047LMissenseCOSM776124 T201047CAT--CGTA → GH1047RMissenseCOSM775ESCC26 T9545GAG -- GCGA → CE545AMissenseCOSM12458120 T9555AGG -- AAGG → AR555KMissenseCOSM171615836 T9524AGG -- AAGG → AR524KMissenseCOSM532454 T201030AAA -- AGAA → GK1030RMissenseNot reportedCME101 M201053ACA -- AAAC → AT1053KMissenseNot reportedCME/ESCC -- chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC -- esophageal squamous cell carcinoma without chagasic megaesophagus; CME -- chagasic megaesophagus without esophageal squamous cell carcinoma. A -- adenine; C -- cytosine; G -- guanine; T -- thymine. WT -- wild-type; MUT -- mutantFig. 2*PIK3CA* protein and missense mutation overview

No significant associations were observed between the *PIK3CA* mutation status and patients pathological features (Table [4](#Tab4){ref-type="table"}). Furthermore, we assessed the role of *PIK3CA* mutations on patients' overall survival in both groups affected by cancer (CM/ESCC and ESCC) (Fig. [3](#Fig3){ref-type="fig"}). In CM/ESCC group, we observed that the presence of *PIK3CA* mutations was significantly associated with a lower survival rate from the diagnosis of cancer compared to wild-type patients (Fig. [3](#Fig3){ref-type="fig"}a). The mean patients' overall survival in cases from the CM/ESCC group mutated for the *PIK3CA* was 5 months, in comparison with 2.0 years for wild-type *PIK3CA* patients (Log-rank, *p* \< 0.001) (Table [5](#Tab5){ref-type="table"}).Table 4Association between *PIK3CA* mutation status with main clinical-pathological features in the three groupsVariable*PIK3CA* geneCM/ESCC groupESCC groupCM groupCategoryWTMUTp-valueWTMUTp-valueWTMUT*p*-valueAlcohol consumptionNo6 (35.3%)1 (20%)1.000^\*\*^7 (21.2%)1 (20%)1.000^\*\*^19 (70.4%)1 (100%)1.000^\*\*^Yes11 (64.7%)4 (80%)26 (78.8%)4 (80%)8 (29.6%)0 (0%)Tobacco consumptionNo4 (23.5%)0 (0%)0.535^\*\*^5 (15.2%)1 (20%)1.000^\*\*^15 (100%)1 (100%)1.000^\*\*^Yes13 (76.5%)5 (100%)28 (84.8%)4 (80%)12 (44.4%)0 (0%)Tumor differentiationWell4 (22.2%)1 (25%)1.000^\*\*^7 (22.6%)0 (0%)0.171^\*\*^NANANAModerate13 (72.2%)3 (75%)21 (67.7%)3 (60%)NANAPoorly1 (5.6%)0 (0%)3 (9.7%)2 (40%)NANATNM StagingI e II4 (28.6%)0 (0%)0.541^\*\*^15 (46.9%)1 (20%)0.421^\*\*^NANANAIII e IV10 (71.4%)3 (100%)17 (53.1%)4 (80%)NANAMegaesophagus degreeGI/GII7 (41.2%)3 (60%)0.406^\*\*^NANANA3 (11.1%)1 (100%)0.143^\*\*^GIII/GIV10 (58.8%)2 (40%)NANA24 (88.9%)0 (0%)*TP53* gene \[[@CR7]\]WT9 (50%)2 (40%)1.000^\*\*^20 (60.6%)2 (40%)0.632^\*\*^26 (96.3%)1 (100%)1.000^\*\*^MUT9 (50%)3 (60%)13 (39.4%)3 (60%)1 (3.7%)0 (0%)^\*\*^Fisher's exact test; ^\*\*\*^Analysis of variance. CME/ESCC -- chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC -- esophageal squamous cell carcinoma without chagasic megaesophagus; CME -- chagasic megaesophagus without esophageal squamous cell carcinoma. N -- number of cases; SD -- standard deviation; NA -- not applicable; WT -- wild-type; MUT -- mutatedFig. 3Cumulative survival of patients associated with the *PIK3CA* gene status. The red curves represent patients with mutation and the blue curves represent wild-type patients. **a** CM/ESCC -- chagasic megaesophagus associated with squamous cell carcinoma of the esophagus; **b** ESCC -- squamous cell carcinoma of the esophagus; MUT -- mutant; WT -- wild-typeTable 5The time and average of patients' overall survival according to *PIK3CA* mutation statusGroupsTimeVariableTotalN events6 months1 year3 years5 yearsMedian survival*p*-valueCM/ESCCWT131079.4%72.2%43.3%28.9%2 years**\< 0.001** ^**\***^MUT5520.0%0.0%0.0%0.0%5 monthsESCCWT242282.6%64.7%32.6%14.5%2 years0.405MUT4480.0%80.0%60.0%0.0%2.5 years^\*^Log-rank test. CM/ESCC -- chagasic megaesophagus associated with esophageal squamous cell carcinoma; ESCC -- esophageal squamous cell carcinoma without chagasic megaesophagus; WT -- wild-type; MUT -- mutated; Bold numbers - statistical significance

Additionally, we evaluated the association of *PIK3CA* and *TP53* mutation status, and no association was found (Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec10}
==========

Among the several risk factors for the development of ESCC, the chagasic megaesophagus (late complication of Chagas' disease) has been a minor etiological factor and little explored \[[@CR4]\]. Nevertheless, Chagas' disease is still an important public health problem, particularly in Latin-America, where approximately 20 million people are infected with Chagas' disease and approximately 6--7% of these people will develop chagasic megaesophagus \[[@CR5], [@CR16]\].

In the present study, we investigated the frequency of *PIK3CA* mutations in regions of hotspot (exons 9 and 20) in patients with chagasic megaesophagus associated with esophageal squamous cell carcinoma (CM/ESCC) and compared with patients with esophageal squamous cell carcinoma without chagasic megaesophagus (ESCC) and patients with chagasic megaesophagus without esophageal squamous cell carcinoma (CM). We observed that patients in the CM/ESCC group had a higher frequency of mutations (5/23, 21.7%) followed by patients in the ESCC group (4/38, 10.5%), and in the CM group (1/28, 3.6%). This is the first report of *PIK3CA* mutation in ESCC that developed in the context of chagasic megaesophagus and the significant frequency of mutations (\~ 22%) suggest that *PIK3CA* plays an important role in the carcinogenesis of CM/ESCC patients. Moreover, the presence of *PIK3CA* mutation in a benign lesion further supports the putative role of chagasic megaesophagus as an ESCC-related condition. The frequency of mutations identified in our study is in line with that reported in the literature for ESCC patients, with frequencies varying from 2.2 to 32.8% (Table [6](#Tab6){ref-type="table"}) \[[@CR9], [@CR17]--[@CR33]\]. This variation can be due to several factors, such as type of tissue (frozen vs FFPE), distinct methodologies for mutation screening and distinct ethnic groups of patients. (Table [6](#Tab6){ref-type="table"}).Table 6Frequency of *PIK3CA* mutations identified in patients with esophageal squamous cell carcinoma worldwideReferencesYearCountry (Region)Patients of study*PIK3CA* mutated (%)Type of sampleTechniquesMori et al. \[[@CR24]\]2008Japan882.2%FTDirect SequencingWang et al. \[[@CR30]\]2013China763.9%FTDirect SequencingAkagi et al. \[[@CR17]\]2009Japan527.7%FFPEDirect SequencingKim et al. \[[@CR21]\]2016Korea53410.5%FFPEDirect SequencingPhillips et al. \[[@CR25]\]2006Australia3511.8%FFPEDirect SequencingZheng et al. \[[@CR33]\]2016China7919.7%FTPyrosequencingShigaki et al. \[[@CR27]\]2013China21921.0%FTPyrosequencingLiu et al. \[[@CR23]\]2017China21022.9%FFPEPyrosequencingBaba et al. \[[@CR18]\]2015Japan44023.0%FFPEPyrosequencingYang et al. \[[@CR31]\]2017China244.2%FFPENGSSong et al. \[[@CR28]\]2014China1584.5%FTNGSLin et al. \[[@CR22]\]2014China1397.0%FFPENGSGao et al. \[[@CR19]\]2014Japan1339.0%FTNGSSawada et al. \[[@CR26]\]2016Japan14410.4%FTNGSTCGA et al. \[[@CR9]\]2017Western and Eastern9013.0%FTNGSYokota et al. \[[@CR37]\]2018Japan12613.5%FFPENGSZhang et al. \[[@CR32]\]2015China9017.0%FTNGSWang et al. \[[@CR29]\]2015USA7124.0%FFPENGSNGS -- next generation sequencing; FFPE -- formalin-fixed paraffin-embedded tissue; FT -- fresh frozen tissue

The *PIK3CA* gene is often mutated in several tumors types and most of its mutations occur in hotspot regions, such as E542K and E545A located in the helical domain (exon 9), and H1047R and H1047L in the kinase domain (exon 20) \[[@CR11]\]. These mutations lead to the activation of the PIK3 pathway and have a great potential in oncogenic activities \[[@CR11]\]. Interestingly, most of these mutations (E545A, H1047R and H1047L) occurred in patients in the CM/ESCC group and only one (E545A) in one patient in the ESCC group. We also identified other previously described important mutations (Table [3](#Tab3){ref-type="table"}), the D549H mutation observed in the CM/ESCC group was reported in vulva and hepatocellular cancer \[[@CR34]\]; R524K mutation found in the ESCC group was reported in colorectal cancer \[[@CR35]\]; and the R555K mutation was reported in ovary cancer \[[@CR36]\]. Interestingly, it is important to note that we identified three mutations in exon 20 that have not yet been reported (A1027D and K1030R in CM/ESCC group; T1053K in CM group). All these mutations occurred in patients with chagasic megaesophagus whose mutational profile of *PIK3CA* was never reported.

Importantly, we observed that CM/ESCC patients harboring *PIK3CA* mutations were associated with lower overall survival, suggesting its role as a prognostic biomarker in this group of patients. Interestingly, the results of our analyzes of the survival of the mutated patients differ from those reported by others studies, especially in regions of some risk such as Asia, in which patients with ESCC with mutations of the *PIK3CA* gene had a favorable overall survival compared to patients wild-type \[[@CR37]\].

Notably, inhibitors of the PIK3-Akt-mTOR pathway have been developed as cancer target therapy alternatives, and patients harboring *PIK3CA* gene mutations could be potential candidates for such therapeutic approach \[[@CR14]\]. Interestingly, phase I and II clinical trials using pan-*PIK3CA* agents (PIK3-class I), such as buparlisib (BKM120), an oral agent that affects α, β, γ and δ isoforms of PI3K \[[@CR38]\], showed efficacy in several solid tumors, including head and neck cancer \[[@CR39]\]. Copanlisib (BAY80--6946), an intravenous agent that affects α and δ isoforms of PI3K, also showed promising results in non-Hodgkin's lymphomas \[[@CR40]\]; as well as pictilisib (GDC-0941), an oral agent that affects γ and δ isoforms of PI3K, where a good response was reported in breast, colorectal, ovarian and non-small cell lung cancer \[[@CR41]\]. Therefore, we can hypothesize that a subset of ESCC and CM/ESCC patients with *PIK3CA* mutations may benefit from these targeted-therapies and consequently improve their dismal survival.

In conclusion, this is the first study that analyzed and identified *PIK3CA* activating mutations in patients with esophageal squamous cell carcinomas associated with chagasic megaesophagus (CM/ESCC), which were associated with a worse outcome. Moreover, the identification of mutations in benign chagasic megaesophagus suggests their putative role in the etiology of esophageal squamous cell carcinoma and opens new opportunities for the treatment of these neglected patients with targeted-therapies.

CM

:   Chagasic megaesophagus

ESCC

:   Esophageal squamous cell carcinoma

FFPE

:   Formalin-fixed paraffin-embedded

MSI

:   Microsatellite instability

PCR

:   Polymerase chain reaction

Funding {#FPar1}
=======

This study was financially supported by CAPES and FAPESP - Fundação de Amparo à Pesquisa do Estado de São Paulo \[Grant number 2015/20077--3 to FFM\] and Barretos Cancer Hospital internal research funds (PAIP).

Availability of data and materials {#FPar2}
==================================

All data generated or analyzed during this study are included in this published article.

FFM participated in the conception of the study, data collection, analysis and interpretation of the results, and draft of the manuscript. ACC, CFL, ATTO, CSN, SRMS, EC, SJA, MAMR and MACAH participated in the acquisition and quality assessment of the data collection and results interpretation. ALF and DPG participated in the, data collection, analysis and interpretation and draft of the manuscript. RMR participated in the designed, supervision, data interpretation and drafting and final revision of the manuscript. All authors gave final approval of the manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

The local ethic committees approved the study (number 1010/2015).

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests for this present study.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
